Annovis Bio Inc. (NYSE: ANVS) will deliver three presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston, the company announced. The presentations will focus on the company's investigational oral therapy buntanetap, including its mechanism of action targeting neurotoxic proteins, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer's disease, and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer's drug candidates. The program includes an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, and two poster presentations on Nov. 16-17, one of which will be given by Chief Scientific Officer Cheng Fang.
The announcements matter because they arrive as Annovis approaches a pivotal clinical data readout in early 2027 and prepares for a New Drug Application. For investors and patients alike, the CTAD platform offers a critical venue to validate the scientific rationale behind buntanetap, which is designed to inhibit the translation of multiple neurotoxic proteins—including APP and amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions, a goal that, if achieved, would represent a significant advance in a field where disease-modifying therapies remain scarce.
The Phase 3 trial design and baseline characteristics presentation is particularly important because it will give the scientific community a first detailed look at the study's structure and patient population, factors that can influence the interpretability of eventual results. Meanwhile, the AI-driven blood-brain barrier permeability work underscores a growing trend in drug development: using computational tools to prioritize candidates most likely to reach their targets in the brain. If validated, such an approach could streamline future Alzheimer's research and reduce costly late-stage failures.
Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company's newsroom at https://nnw.fm/ANVS.
The CTAD presentations also serve as a prelude to the company's anticipated Phase 3 data, which could be a major catalyst for Annovis and for the broader Alzheimer's treatment landscape. Positive results would not only bolster the case for buntanetap but also reinforce the potential of multi-target approaches in neurodegenerative disease. As the company prepares for an NDA, the scientific scrutiny at CTAD may help shape investor expectations and clinical adoption. For a full press release, visit https://nnw.fm/2k4SQ.
